AKTX

Akari Therapeutics, Plc

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$6.51

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %3 / %30

Non-compliant assets / Total market cap %0 / %30

Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.

Website

Analysis (Turkish): AKTX Hissesi Caiz mi, Helal mi? Akari Therapeutics, Plc Katılım Analizi